Indo-Bangla Pharmaceuticals Limited (DSE:IBP)

Market Cap	1.43B
Revenue (ttm)	198.02M
Net Income (ttm)	-32.60M
Shares Out	116.21M
EPS (ttm)	-0.27
PE Ratio	n/a
Forward PE	n/a
Dividend	0.02 (0.12%)
Ex-Dividend Date	Dec 8, 2025

Volume	948,899
Average Volume	562,584
Open	12.50
Previous Close	12.50
Day's Range	12.20 - 12.70
52-Week Range	8.50 - 15.60
Beta	0.07
RSI	59.16
Earnings Date	Jan 15, 2026

About DSE:IBP

Indo-Bangla Pharmaceuticals Limited engages in the manufacture and sale of various medicines, medical preparations drugs, and chemicals in Bangladesh and internationally. The company’s principal products include Omeprazole, Esomeprazole, Dexamethasone, Domperidone, Metronidazole, Montelukast, Paracetamol, Sildenafil Citrate, and several other formulations. It markets its products in various forms, such as tablets, capsules. Indo-Bangla Pharmaceuticals Limited was founded in 1954 and is based in Dhaka, Bangladesh.

• Industry: Pharmaceutical Preparations
• Founded: 1954
• Employees: 127
• Stock Exchange: Dhaka Stock Exchange
• Ticker Symbol: IBP

Financial Performance

In 2025, DSE:IBP's revenue was 184.18 million, an increase of 4.27% compared to the previous year's 176.64 million. Losses were -36.83 million, -10.12% less than in 2024.